Результаты поиска

Litigations for HIV Related Complications

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… The GP(general practitioner) then initiated a regimen consisting of didanosine, lamivudine, and saquinavir for HIV infection. At that time, testing for HIV viral load was not generally available to the medical community, but became procurable in 1997. …

Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.

The objective of this two-part review is to present a current and comprehensive understanding of the diagnosis and management of plasmablastic lymphoma. The first part, which was published previously, focused on the study of epidemiology, etiology, clinicopathological characteristics, differential diagnosis, prognostic variables, and the impact of plasmablastic lymphoma on specific populations. This second part addresses the difficult topic of the treatment of plasmablastic lymphoma, specifically examining both the conventional, consolidated approach and the novel therapeutic strategy.

Совпадение в полном тексте источника
… In addition to tenofovir and emtricitabine (FTC) or lamivudine (3TC), a third HIV drug should be administered. 174 , 175 Tenofovir alafenamide (TAF) should be preferred over tenofovir disoproxilfumarate (TDF) because it has a more favorable safety profile and is equally effective against HBV. 175 Therefore …

SARS-CoV-2 drug resistance and therapeutic approaches.

In light of the transition of COVID-19 from a pandemic to an endemic phase, there is still a dire need to address challenges associated with drug resistance, particularly among immunocompromised and high-risk populations. This review explores the current state of research on SARS-CoV-2 drug resistance and underscores the ongoing need for effective therapeutic strategies. It critically evaluates existing knowledge on resistance mechanisms and therapeutic options, aiming to consolidate information and highlight areas for future research. By examining the complex interactions between the virus an

Совпадение в полном тексте источника
… Lamivudine, another HIV drug, showed antiviral activity against SARS-CoV-2 in vitro [ 182 ] and reduced infection rates in Hepatitis B patients, making it a promising candidate for COVID-19 treatment [ 183 ]. Abacavir also shows promise due to its ability to inhibit viral polymerase [ 184 ]. …

Forecasting drug utilization and expenditure in a metropolitan health region.

BackgroundNew pharmacological therapies are challenging the healthcare systems, and there is an increasing need to assess their therapeutic value in relation to existing alternatives as well as their potential budget impact. Consequently, new models to introduce drugs in healthcare are urgently needed. In the metropolitan health region of Stockholm, Sweden, a model has been developed including early warning (horizon scanning), forecasting of drug utilization and expenditure, critical drug evaluation as well as structured programs for the introduction and follow-up of new drugs. The aim of this

Совпадение в полном тексте источника
… The management of chronic hepatitis B (HBV) has improved over the last decade with the development of new drugs such as lamivudine, adefovir and dipivoxil, in addition to interferon (IFN)-alpha therapy [ 43 ]. …

Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.

The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the properties originally attributed to this cytokine family, with schedules reflecting only their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity. As current schedules of treatment for chronic hepatitis C and for hematological and solid tumors, based on the continuous administration of recombinant type I IFN or pegylated formulations, disregard viral resistance, host genetic variants predicting treatment outcom

Совпадение в полном тексте источника
… Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217 15371578 10.1056/NEJMoa040431 18 Scagnolari C. Antonelli G. …

Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.

BackgroundChimeric antigen receptor T (CAR-T) cell therapy has emerged as a potent treatment for relapsed or refractory multiple myeloma, demonstrating significant clinical efficacy. Despite these advances, treatment-related toxicities, particularly infections, pose a significant challenge to patient safety.MethodsThis review synthesizes current knowledge on the mechanisms underlying post-CAR-T therapy infections, focusing on the interplay between immune dysfunction, host factors, and treatment-induced toxicity. It provides a comprehensive analysis of the temporal and individual variability in

Совпадение в полном тексте источника
… as entecavir), prophylactic treatment with entecavir for at least 6 months is recommended to reduce the risk of viral reactivation, along with strict monitoring through liver function tests or HBV DNA testing. 65 Additionally, studies have explored the antiviral prophylactic effects of entecavir and lamivudine …

Клиническое представление лептоспироза: ретроспективное исследование 34 Пациенты поступили в одно учебное заведение во Франции.

Лептоспироз имеет весьма изменчивое клиническое представление, которое может быть связано с различными заражающими сероварами, факторами хост-компьютеров или их комбинацией. Это исследование проводилось ретроспективно 34 Число пациентов с серологическим подтвержденным лептоспирозом, принятых в течение отчетного периода 1992-2002. Наиболее частыми симптомами при поступлении в школу были лихорадка (см.100%), головная боль75%), миальгии55%), артхальгии45%) и рвотой (т.е.39%). Применяемые лабораторные исследования включали в себя лимфопенцию (см.85%), тромбоцитопенсия75%), повышенные ферменты пече

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

BACKGROUND: Antiretroviral drugs (ARV) reduce viral replication and can reduce mother-to-child transmission of HIV either by lowing plasma v … 8.72 to 79.28) and 3 to 4 months (Efficacy 37.00%; 95% CI 3.68 to 70.32) but not at birth.ZDV plus lamivudine (3TC) given to mothers from 36 weeks gestation, during labour and for 7 days after delivery and to babies for the first 7 days of life (PETRA 'regimen A') significantly reduced HIV infection (Efficacy 63.00%; 95% CI 41.44 to 84.56) and a combined en …

Doubly blind: a systematic review of gender in randomised controlled trials.

BackgroundAlthough observational data show social characteristics such as gender or socio-economic status to be strong predictors of health, their impact is seldom investigated in randomised controlled studies (RCTs).Objective & designUsing a random sample of recent RCTs from high-impact journals, we examined how the most often recorded social characteristic, sex/gender, is considered in design, analysis, and interpretation. Of 712 RCTs published from September 2008 to 31 December 2013 in the Annals of Internal Medicine, British Medical Journal, Lancet, Canadian Medical Association Journal, or

Совпадение в полном тексте источника
… Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18. doi: 10.1056/NEJMoa1215541. 72. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. …

Passive Monoclonal and Polyclonal Antibody Therapies

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.

The therapeutic options available for patients with multiple myeloma have greatly expanded over the past decade and incorporating these novel agents into routine clinical practice has significantly improved outcomes. The next generation of therapeutics is available for relapsed and refractory patients either as standard of care or in clinical trial, and these drugs represent a generational paradigm shift. Patients now have access to a multitude of novel immunotherapeutics, including monoclonal antibodies, an antibody-drug conjugate, chimeric antigen receptor T-cells (CAR-T), and bispecific T-c

Совпадение в полном тексте источника
… Patients may continue mAb treatment alongside prophylaxis or preemptive therapy with either tenofovir or entecavir (not lamivudine due to low-resistance thresholds with this agent). 55 Monitoring and treatment of active hepatitis B disease requires consultation with a hepatologist to determine duration …

Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.

Cancer has been one of the most dominant causes of mortality globally over the last few decades. In cancer treatment, the selective targeting of tumor cells is indispensable, making it a better replacement for conventional chemotherapies by diminishing their adverse side effects. While designing a drug to be delivered selectively in the target organ, the drug development scientists should focus on various factors such as the type of cancer they are dealing with according to which drug, targeting moieties, and pharmaceutical carriers should be targeted. All published articles have been collecte

Surrogate Biomarkers in Gene Therapy for Orphan Diseases: Validation, Application, and Regulatory Aspects.

The development of gene therapies for rare hereditary disorders is hindered by small patient cohorts, incomplete characterization of natural disease history, and the impracticality of conducting long-term clinical trials. Surrogate biomarkers-quantifiable indicators predictive of clinical outcomes-represent a promising strategy to accelerate the evaluation of therapeutic efficacy. This review examines the role of surrogate endpoints in gene therapy, outlining essential validation criteria, including biological plausibility, analytical reproducibility, and clinical predictive value. Regulatory

Совпадение в полном тексте источника
… Impact of Dolutegravir Plus Lamivudine as First-Line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood J. Infect. Dis. 2025 231 600 610 10.1093/infdis/jiae530 39465671 PMC11911789 22. Patel M.M. Adrada B.E. …

Свойства антиракера ВИЧ-ингибатора Нелфинавира.

Традиционные методы лечения рака могут потерять свою эффективность после появления новых мутации или развития химиотерапии. Несвоевременная диагностика, высокая стоимость лечения и потребность в высокоэффективной инфраструктуре для лечения раковых заболеваний затрудняют доступ к надлежащему лечению в условиях с низким уровнем доходов и ограниченными ресурсами. Переориентация утвержденных лекарственных средств на лечение рака может привести к снижению стоимости и сокращению сроков разработки новых лекарственных средств и к ускорению появления новых и эффективных вариантов лечения для нуждающихс

Совпадение в полном тексте источника
… For instance, Niehuse et al. reported a case of complete regression of AIDS-associated Kaposi’s sarcoma (KS) in a 5-year-old child undergoing HAART regimen consisting of HIV-PI nelfinavir and reverse transcriptase inhibitors zidovudine and lamivudine [ 7 ]. …

Micro and nanotechnologies: The little formulations that could.

The first publication of micro- and nanotechnology in medicine was in 1798 with the use of the Cowpox virus by Edward Jenner as an attenuated vaccine against Smallpox. Since then, there has been an explosion of micro- and nanotechnologies for medical applications. The breadth of these micro- and nanotechnologies is discussed in this piece, presenting the date of their first report and their latest progression (e.g., clinical trials, FDA approval). This includes successes such as the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines from Pfizer, Moderna, and Janssen (

Совпадение в полном тексте источника
… Furthermore, rilpivirine has one of the lowest doses required of all ARTs (25 mg daily), which in some cases is orders of magnitude less mass than needed for other common ARTs (e.g., emtricitabine 200 mg/day, lamivudine 300 mg/day, abacavir 600 mg/day). …

Genus Sophora: a comprehensive review on secondary chemical metabolites and their biological aspects from past achievements to future perspectives.

Sophora is deemed as one of the most remarkable genera of Fabaceae, and the third largest family of flowering plants. The genus Sophora comprises approximately 52 species, 19 varieties, and 7 forms that are widely distributed in Asia and mildly in Africa. Sophora species are recognized to be substantial sources of broad spectrum biopertinent secondary metabolites namely flavonoids, isoflavonoids, chalcones, chromones, pterocarpans, coumarins, benzofuran derivatives, sterols, saponins (mainly triterpene glycosides), oligostilbenes, and mainly alkaloids. Meanwhile, extracts and isolated compoun

Emerging therapeutics in the management of COVID-19.

The severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019, COVID-19) pandemic has placed a tremendous burden on healthcare systems globally. Therapeutics for treatment of the virus are extremely inconsistent due to the lack of time evaluating drug efficacy in clinical trials. Currently, there is a deficiency of published literature that comprehensively discusses all therapeutics being considered for the treatment of COVID-19. A review of the literature was performed for articles related to therapeutics and clinical trials in the context of the current COVID-19 pandemic. We

Совпадение в полном тексте источника
… ct2/show/NCT04261907 NLM Identifier: NCT04261907 45 Wang RR Yang QH Luo RH Peng YM Dai SX Zhang XJ Chen H Cui XQ Liu YJ Huang JF Chang JB Zheng YT Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine …

Abstracts cont.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Epidemiology of infections in cancer patients.

Although major advances in the care of cancer patients over the past several decades have resulted in improved survival, infectious complications remain a significant cause of morbidity and mortality. To successfully identify, treat, and prevent infections, a comprehensive understanding of risk factors that predispose to infection and of commonly encountered pathogens is necessary. In addition, clinicians must keep abreast of the changing epidemiology of infections in this population. As therapeutic modalities continue to evolve, as established pathogens become increasingly drug resistant, and

Совпадение в полном тексте источника
… Prophylactic agents such as lamivudine, adefovir, entecavir, or tenofovir should be started as early as possible before initiating immunosuppressive therapy in HBsAg positive patients. …

COVID-19 Therapeutic Options Under Investigation.

Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexame